The effect of Bevacizumab on recurrent pterygia

The effect of local injection of Bevacizumab on pterygial size in patients with recurrence of pterygia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010054856N1

Enrollment

Registered

2011-05-02

Start date

2010-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pterygium. Pterygium

Interventions

Injection of 1.25 mg Bevacizumab in Pterygial Bed.

Treatment - Surgery

Injection of 1.25 mg Bevacizumab in Pterygial Bed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Recurrence of pterygia after surgical excision Exclusion criteria: History of any other ophthalmic surgery

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pterygium size. Timepoint: Before intervention, 1 week, 1 month and 3 monthes after intervention. Method of measurement: mili meter with Slit Lamp.	—

Secondary

Measure	Time frame
Angiogenesis. Timepoint: Befor intervention, 1 week, 1 month and 3 monthes after intervention. Method of measurement: Based on Fondues Camera picture.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Alishiri MD.

Ophthalmology department of Baqiyatallah hospital

ophthalmology110@yahoo.com+98 82162436

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026